Sun, May 19, 2013, 4:51 AM EDT - U.S. Markets closed
Today's decision from the Federal Appeals Court:http://www.cafc.uscourts.gov/images/stories/opinions-orders/10-1102-1103.pdfBottom line (p22): "we accordingly reverse the district court's judgment finding that Excela's filing of the ANDA is an act of infringement."So Excela is free to produce generic version of Alphagan, which is (was) worth about $400M/yr to AGN. Not good.